DOCICAR: Cardiac Dysfunction in Cirrhosis

NCT00250315 · Status: COMPLETED · Type: OBSERVATIONAL

Last updated 2007-11-01

No results posted yet for this study

Summary

Patients with cirrhosis have a altered cardiac response to stress. This study evaluate the cardiac response by MRI during dobutamine stress. Hypothesis: impared increase in cardiac output, cardiac index, ejection fraction.

Conditions

  • Cirrhosis
  • Cirrhotic Cardiomyopathy

Interventions

DRUG

Dobutamine

Sponsors & Collaborators

  • Hvidovre University Hospital

    lead OTHER

Principal Investigators

  • Søren Møller, DrMsci, MD · Hvidovre University Hospital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-11-30
Completion
2007-10-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00250315 on ClinicalTrials.gov